Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis
Objectives: To compare the liver safety profile of interferon ? (IFN ?) and teriflunomide in patients with multiple sclerosis. Methods: A network meta-analysis was carried out following the Cochrane Collaboration methodology. All trials comparing all types of IFN ? with teriflunomide, or disease-mod...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2018
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/22632
- Acceso en línea:
- https://doi.org/10.1016/j.msard.2018.09.014
https://repository.urosario.edu.co/handle/10336/22632
- Palabra clave:
- Alemtuzumab
Beta interferon
Daclizumab
Fingolimod
Glatiramer
Placebo
Teriflunomide
Beta interferon
Crotonic acid derivative
Immunologic factor
Teriflunomide
Toluidine derivative
Article
Drug efficacy
Drug safety
Human
Hypertransaminasemia
Liver function
Liver function test
Meta analysis
Multiple sclerosis
Systematic review
Toxic hepatitis
Treatment outcome
Comparative study
Drug effect
Liver
Multiple sclerosis
Toxic hepatitis
Chemical and drug induced liver injury
Crotonates
Humans
Immunologic factors
Interferon-beta
Liver
Multiple sclerosis
Toluidines
Interferon ?
Liver safety profile
Multiple sclerosis
Teriflunomide
- Rights
- License
- Abierto (Texto Completo)
id |
EDOCUR2_2b29a399b3fd098991d04120f85e8b61 |
---|---|
oai_identifier_str |
oai:repository.urosario.edu.co:10336/22632 |
network_acronym_str |
EDOCUR2 |
network_name_str |
Repositorio EdocUR - U. Rosario |
repository_id_str |
|
spelling |
59ded4c9-10b6-4b63-928a-2a6f79338dc477f7c241-ad5c-4c20-8027-4346cd7252a8fc8aca80-c009-4364-90f4-2f3cc56f4415c0262846-5226-43f6-8445-4b9ec0a50a9b7914139860080d51910-5fa5-4f27-bb27-9c24085d036f2020-05-25T23:57:13Z2020-05-25T23:57:13Z2018Objectives: To compare the liver safety profile of interferon ? (IFN ?) and teriflunomide in patients with multiple sclerosis. Methods: A network meta-analysis was carried out following the Cochrane Collaboration methodology. All trials comparing all types of IFN ? with teriflunomide, or disease-modifying drugs, or placebo in RRMS were included. An indirect comparison network meta-analysis within a Bayesian framework with STATA (version 13.0) was done for this study. Results: The database searches yielded 284 titles, with 15 records as duplicates. One study was identified by manually searching. Thirteen articles were included in the systematic review. Twelve studies compared IFN ? (4203 patients) vs another DMT. Four studies evaluated the effectiveness and safety of teriflunomide (906 patients) vs another DMT. Six studies reported drug-induced liver injury as per the Hy's Law. However, only one study had a direct comparison and reported no cases of liver toxicity in either group, so it was not possible to estimate the OR. The indirect comparisons metanalysis shows that there was no statistically-significant difference between teriflunomide and IFN ? (OR 1.09, 95% CI 0.02–2.16). Conclusions: There were no significant difference when comparing IFN ? and teriflunomide in terms of liver failure or elevation of transaminases. © 2018application/pdfhttps://doi.org/10.1016/j.msard.2018.09.01422110348https://repository.urosario.edu.co/handle/10336/22632engElsevier B.V.200192Multiple Sclerosis and Related DisordersVol. 26Multiple Sclerosis and Related Disorders, ISSN:22110348, Vol.26,(2018); pp. 192-200https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053856722&doi=10.1016%2fj.msard.2018.09.014&partnerID=40&md5=56fff51e5923b216bcbec854c32a836aAbierto (Texto Completo)http://purl.org/coar/access_right/c_abf2instname:Universidad del Rosarioreponame:Repositorio Institucional EdocURAlemtuzumabBeta interferonDaclizumabFingolimodGlatiramerPlaceboTeriflunomideBeta interferonCrotonic acid derivativeImmunologic factorTeriflunomideToluidine derivativeArticleDrug efficacyDrug safetyHumanHypertransaminasemiaLiver functionLiver function testMeta analysisMultiple sclerosisSystematic reviewToxic hepatitisTreatment outcomeComparative studyDrug effectLiverMultiple sclerosisToxic hepatitisChemical and drug induced liver injuryCrotonatesHumansImmunologic factorsInterferon-betaLiverMultiple sclerosisToluidinesInterferon ?Liver safety profileMultiple sclerosisTeriflunomideSafety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysisarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Salas P.A.O.Parra C.O.Florez C.E.P.Goez L.M.Vélez van Meerbeke, Alberto FranciscoRodriguez J.H.10336/22632oai:repository.urosario.edu.co:10336/226322022-05-02 07:37:17.652795https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co |
dc.title.spa.fl_str_mv |
Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis |
title |
Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis |
spellingShingle |
Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis Alemtuzumab Beta interferon Daclizumab Fingolimod Glatiramer Placebo Teriflunomide Beta interferon Crotonic acid derivative Immunologic factor Teriflunomide Toluidine derivative Article Drug efficacy Drug safety Human Hypertransaminasemia Liver function Liver function test Meta analysis Multiple sclerosis Systematic review Toxic hepatitis Treatment outcome Comparative study Drug effect Liver Multiple sclerosis Toxic hepatitis Chemical and drug induced liver injury Crotonates Humans Immunologic factors Interferon-beta Liver Multiple sclerosis Toluidines Interferon ? Liver safety profile Multiple sclerosis Teriflunomide |
title_short |
Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis |
title_full |
Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis |
title_fullStr |
Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis |
title_full_unstemmed |
Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis |
title_sort |
Safety liver profile of teriflunomide versus interferon ? in multiple sclerosis: Systematic review and indirect comparison meta-analysis |
dc.subject.keyword.spa.fl_str_mv |
Alemtuzumab Beta interferon Daclizumab Fingolimod Glatiramer Placebo Teriflunomide Beta interferon Crotonic acid derivative Immunologic factor Teriflunomide Toluidine derivative Article Drug efficacy Drug safety Human Hypertransaminasemia Liver function Liver function test Meta analysis Multiple sclerosis Systematic review Toxic hepatitis Treatment outcome Comparative study Drug effect Liver Multiple sclerosis Toxic hepatitis Chemical and drug induced liver injury Crotonates Humans Immunologic factors Interferon-beta Liver Multiple sclerosis Toluidines Interferon ? Liver safety profile Multiple sclerosis Teriflunomide |
topic |
Alemtuzumab Beta interferon Daclizumab Fingolimod Glatiramer Placebo Teriflunomide Beta interferon Crotonic acid derivative Immunologic factor Teriflunomide Toluidine derivative Article Drug efficacy Drug safety Human Hypertransaminasemia Liver function Liver function test Meta analysis Multiple sclerosis Systematic review Toxic hepatitis Treatment outcome Comparative study Drug effect Liver Multiple sclerosis Toxic hepatitis Chemical and drug induced liver injury Crotonates Humans Immunologic factors Interferon-beta Liver Multiple sclerosis Toluidines Interferon ? Liver safety profile Multiple sclerosis Teriflunomide |
description |
Objectives: To compare the liver safety profile of interferon ? (IFN ?) and teriflunomide in patients with multiple sclerosis. Methods: A network meta-analysis was carried out following the Cochrane Collaboration methodology. All trials comparing all types of IFN ? with teriflunomide, or disease-modifying drugs, or placebo in RRMS were included. An indirect comparison network meta-analysis within a Bayesian framework with STATA (version 13.0) was done for this study. Results: The database searches yielded 284 titles, with 15 records as duplicates. One study was identified by manually searching. Thirteen articles were included in the systematic review. Twelve studies compared IFN ? (4203 patients) vs another DMT. Four studies evaluated the effectiveness and safety of teriflunomide (906 patients) vs another DMT. Six studies reported drug-induced liver injury as per the Hy's Law. However, only one study had a direct comparison and reported no cases of liver toxicity in either group, so it was not possible to estimate the OR. The indirect comparisons metanalysis shows that there was no statistically-significant difference between teriflunomide and IFN ? (OR 1.09, 95% CI 0.02–2.16). Conclusions: There were no significant difference when comparing IFN ? and teriflunomide in terms of liver failure or elevation of transaminases. © 2018 |
publishDate |
2018 |
dc.date.created.spa.fl_str_mv |
2018 |
dc.date.accessioned.none.fl_str_mv |
2020-05-25T23:57:13Z |
dc.date.available.none.fl_str_mv |
2020-05-25T23:57:13Z |
dc.type.eng.fl_str_mv |
article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.spa.spa.fl_str_mv |
Artículo |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1016/j.msard.2018.09.014 |
dc.identifier.issn.none.fl_str_mv |
22110348 |
dc.identifier.uri.none.fl_str_mv |
https://repository.urosario.edu.co/handle/10336/22632 |
url |
https://doi.org/10.1016/j.msard.2018.09.014 https://repository.urosario.edu.co/handle/10336/22632 |
identifier_str_mv |
22110348 |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.relation.citationEndPage.none.fl_str_mv |
200 |
dc.relation.citationStartPage.none.fl_str_mv |
192 |
dc.relation.citationTitle.none.fl_str_mv |
Multiple Sclerosis and Related Disorders |
dc.relation.citationVolume.none.fl_str_mv |
Vol. 26 |
dc.relation.ispartof.spa.fl_str_mv |
Multiple Sclerosis and Related Disorders, ISSN:22110348, Vol.26,(2018); pp. 192-200 |
dc.relation.uri.spa.fl_str_mv |
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85053856722&doi=10.1016%2fj.msard.2018.09.014&partnerID=40&md5=56fff51e5923b216bcbec854c32a836a |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.acceso.spa.fl_str_mv |
Abierto (Texto Completo) |
rights_invalid_str_mv |
Abierto (Texto Completo) http://purl.org/coar/access_right/c_abf2 |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Elsevier B.V. |
institution |
Universidad del Rosario |
dc.source.instname.spa.fl_str_mv |
instname:Universidad del Rosario |
dc.source.reponame.spa.fl_str_mv |
reponame:Repositorio Institucional EdocUR |
repository.name.fl_str_mv |
Repositorio institucional EdocUR |
repository.mail.fl_str_mv |
edocur@urosario.edu.co |
_version_ |
1831928195564175360 |